Differential metabolism of ApoE isoforms in plasma and CSF. (Q35212614)

7 August 2017

1 reference

title

Differential metabolism of ApoE isoforms in plasma and CSF. (English)

1 reference

7 August 2017

2

David M Holtzman

1 reference

7 August 2017

Suzanne E Wahrle

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

7 August 2017

published in

Experimental Neurology

1 reference

7 August 2017

volume

183

1 reference

7 August 2017

issue

1

1 reference

7 August 2017

page(s)

4-6

1 reference

Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

APOE genotype is a major predictor of long-term progression of disability in MS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Comparative in vivo metabolism of apolipoproteins E2 and E4 in heterozygous apoE2/4 subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Alzheimer's disease: genotypes, phenotypes, and treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Apolipoprotein E4: an allele associated with many diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, Gelsolin and AA amyloids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Human apolipoprotein E: the Alzheimer's disease connection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900185-7

10.1016/S0014-4886(03)00185-7

7 January 2021

Identifiers

DOI

1 reference

7 August 2017

1 reference